Exelixis

Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
Endpoints
Roche
Tecentriq
clinical trials
colon cancer
Exelixis
Cotellic
Flag link:
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
Motley Fool
Exelixis
Cabometyx
renal cell carcinoma
Flag link:
Pfizer, Exelixis cancer drugs get FDA approval for wider use
Pfizer, Exelixis cancer drugs get FDA approval for wider use
Reuters
Pfizer
Exelixis
Cabometyx
kidney cancer
Bosulif
blood cancer
Flag link:
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
Motley Fool
Exelixis
Bristol-Myers Squibb
Opdivo
Flag link:
3 Monster Biotech Stocks in the Making
3 Monster Biotech Stocks in the Making
Motley Fool
biotech
Exelixis
Incyte
Vertex Pharmaceuticals
Flag link:
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Investors Business Daily
Amgen
Eli Lilly
JNJ
Exelixis
biotech
Theravance
Bavarian Nordic
Agios
Biohaven Pharmaceuticals
Progenics
Flag link:
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Motley Fool
Exelixis
Bristol-Myers Squibb
kidney cancer
Cabometyx
Opdivo
Yervoy
Flag link:
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Motley Fool
Exelixis
earnings
Cabometyx
Flag link:
Exelixis and Genentech hammer out new deal terms
Exelixis and Genentech hammer out new deal terms
BioPharma Dive
Exelixis
Genentech
Cotellic
melanoma
Flag link:
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Yahoo/Zacks.com
Exelixis
Bristol-Myers Squibb
clinical trials
Opdivo
Opdivo-Cabometyx
renal cell carcinoma
Flag link:
3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates
3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates
Motley Fool
biotech
M&A
Exelixis
Portola Pharmaceuticals
Intercept Pharmaceuticals
Flag link:
Exelixis clears debt, turning eye to future growth
Exelixis clears debt, turning eye to future growth
BioPharma Dive
debt
Exelixis
Flag link:
Exelixis, Inc. Turns a Profit, but Don't Get Too Excited
Exelixis, Inc. Turns a Profit, but Don't Get Too Excited
Motley Fool
Exelixis
earnings
Flag link:
2 Big Reasons Exelixis, Inc. Soared 22% in January
2 Big Reasons Exelixis, Inc. Soared 22% in January
Motley Fool
Exelixis
Cotellic
Roche
cabozantinib
Takeda
Flag link:
On a deal spree, Takeda grabs Japanese cabo rights in $145M pact with Exelixis
On a deal spree, Takeda grabs Japanese cabo rights in $145M pact with Exelixis
Endpoints
Takeda
Japan
cabozantinib
Exelixis
Flag link:
Biotech Stocks: What to Watch in 2017
Biotech Stocks: What to Watch in 2017
Motley Fool
biotech
Seattle Genetics
Exelixis
Clovis Oncology
Kite Pharma
Flag link:
The Best Biopharma CEOs of 2016 Are...
The Best Biopharma CEOs of 2016 Are...
TheStreet.com
Pharma CEOs
Ken Frazier
Merck
David Hung
Medivation
Scott Jackson
Celator Pharmaceuticals
Ed Kaye
Sarepta Therapeutics
Mike Morrissey
Exelixis
Flag link:
The 5 Best Biotech Stocks of 2016
The 5 Best Biotech Stocks of 2016
Motley Fool
biotech
biotech stocks
AXIM Biotech
CoLucid Pharmaceuticals
Corbus
Exelixis
Tesarao
Flag link:
What's Pfizer's Excuse for Not Buying Exelixis?
What's Pfizer's Excuse for Not Buying Exelixis?
Motley Fool
Pfizer
Exelixis
M&A
Cabometyx
kidney cancer
Sutent
Flag link:
3 Things Exelixis Must Do to Survive and Thrive in 2017
3 Things Exelixis Must Do to Survive and Thrive in 2017
Motley Fool
Exelixis
cabozantinib
Cabometyx
Cometriq
Flag link:

Pages